We have observed
7 EP applications
has served for within the last five+ years.
(We consider all applications which have an EP A1 publication dated after January 30, 2013).
Please note, that we only count EP applications,
in which the name of the patent attorney is explicitly mentioned as representative.
These EP applications are:
Pharmaceutical composition containing botulinum neurotoxin A2
Aqueous sustained release compositions of LHRH analogs
Pharmaceutical compositions comprising botulinum neurotoxin
NOVEL IMIDAZOLIDINE-2, 4-DIONE DERIVATIVES
NOVEL IMIDAZOLIDINE-2,4-DIONE DERIVATIVES
THERAPEUTIC USE OF AT LEAST ONE BOTULINUM NEUROTOXIN IN THE TREATMENT OF PAIN ASSOCIATED WITH DIABETIC NEUROPATHY
PRODUCTION OF ACTIVATED CLOSTRIDIAL NEUROTOXINS